DAX+0,53 % EUR/USD+0,02 % Gold+0,45 % Öl (Brent)+0,40 %

Thrombosis Research Institute (TRI) to Announce New Real-World Insights in Atrial Fibrillation at ESC Congress 2018

Nachrichtenagentur: news aktuell
20.08.2018, 18:16  |  424   |   |   
Munich (ots/PRNewswire) -

- Satellite symposium will highlight the breadth of evidence
collected since the establishment of the registry in 2009
- An analysis of the comparative effectiveness of oral anticoagulants
in everyday practice will be presented
- The economic burden of atrial fibrillation (AF) in nine European
countries will be evaluated

The latest results from the Global Anticoagulant Registry in the
Field - Atrial Fibrillation (GARFIELD-AF) will be presented at the
forthcoming ESC Congress 2018, organised by the European Society of
Cardiology, to be held in Munich, Germany, from 25th to 29th August.

Data will be presented as posters, oral presentations and at the
late breaking science session on clinical registries, exploring a
range of areas including the burden attributable to AF in nine
European countries, clinicians' prescribing tendencies, and how the
quality of stroke prevention has changed over time.

The late breaking science session "Registry Results 2" on Tuesday
28th August, 14:30-15:45, (Centre Stage - The Hub) will see
Professors John Camm and Keith Fox present the latest results from
the GARFIELD-AF Registry. Professor Camm will highlight significant
differences in the risk of mortality in favour of OACs (vs. no OAC)
and NOACs (vs. VKAS) even after adjustment for baseline variables.
Professor Fox will present findings that challenge the use of
combined OAC+AP therapy, particularly among those without a clear
indication for AP therapy.

"We are excited to have a strong presence at this year's ESC
Congress, as a result of the wealth of new GARFIELD-AF data, which
will be presented by some of the leading investigators involved in
the registry," said Rt Hon Professor the Lord Ajay K. Kakkar,
Professor of Surgery at University College London and Director of the
Thrombosis Research Institute (TRI), UK.

GARFIELD-AF is the largest ongoing prospective registry of
patients with AF. It is a pioneering, independent outcomes research
initiative led by an international steering committee under the
auspices of the TRI. It has generated at least 2 years of follow-up
data in over 52,000 patients with newly diagnosed AF.

Key results will be unveiled during the TRI Satellite Symposium
which will showcase the wealth of evidence collected since the
establishment of GARFIELD-AF in 2010.

GARFIELD-AF: New light shed on Atrial Fibrillation and its
management

- Satellite Symposium
- Saturday 25th August 2018 from 15.30 - 17.00 (all times CEST) -
Room Vienna - Village 3

Members of the GARFIELD-AF Steering Committee will present a
variety of results, including new insights on the quality of stroke
prevention and its clinical effectiveness in routine care, and
presentations on the real-world record of change in prescribing
practice and outcomes. The new GARFIELD-AF risk score and its online
application will also be discussed. The symposium will also include a
panel discussion led by Professors Jean-Pierre Bassand (France) and
Samuel Z. Goldhaber (USA).

Other key data from GARFIELD-AF will be presented during the
following sessions:

Rapid Fire Abstract Session entitled 'Atrial fibrillation -
Detection, treatment, outcomes' - (11:00 - 12:30, Sunday 26th August;
Location: Agora 2 - Agora)

"The effect of non-recommended dosing of non-vitamin K antagonist
oral anticoagulants (NOACs) on 1-year mortality in patients with
newly diagnosed AF. Results from the GARFIELD-AF registry."

Professor John Camm (UK) will highlight the impact of using
non-recommended doses of NOACs for stroke prevention in in patients
with newly diagnosed AF.

Poster Session 3 - (14.00 - 18.00, Sunday 26th August)

Evaluation of the effect of oral anticoagulants on all-cause
mortality within 3 months of the diagnosis of atrial fibrillation

Karen Pieper (USA) will reveal significant early mortality in
patients with newly diagnosed AF and significant mortality
differences in favour of OACs, even after adjustment for 29 baseline
variables.

The economic burden attributable to atrial fibrillation in nine
European countries

Paolo Cozzolino (Italy) will report that the economic burden of
AF, a growing public health problem, correlates with differences in
management between countries.

Poster Session 5 - (14.00 - 18.00, Monday 27th August)

Why do clinicians withhold anticoagulation in patients with atrial
fibrillation and CHA2DS2-VASc score >=2?

Dr Deborah Siegal (Canada) will report that guideline-based
treatment with oral anticoagulants was associated with better
outcomes, results that emphasise the need to better understand
decision-making to improve oral anticoagulant prescription rates and
outcomes in AF.

Why do clinicians prescribe oral anticoagulation in patients with
atrial fibrillation despite a low CHA2DS2-VASc score?

Frederik Verbrugge (Belgium) will report on the discrepancy
between patient characteristics that predict OAC use in AF patients
with a very low CHA2DS2-VASc score and factors reported by clinicians
Seite 1 von 4
Mehr zum Thema
EuroBerlinUSARealFI


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel